Genzyme’s Tolevamer Misses Endpoint In First Of Two Phase III Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
“We don’t believe tolevamer will be commercialized in the near future,” Genzyme tells “The Pink Sheet” DAILY.
You may also be interested in...
Optimer Rides High After OPT-80 C. Difficile Trial Success
Optimer Pharmaceuticals saw its share price double from around $4 to $8 after it released data from a Phase III trial showing its orally dosed first-in-class macrocyclic antibiotic was at least as good as Vancocin (ViroPharma's oral vancomycin) - and possibly better - at treating the hospital scourge Clostridium difficile.
Optimer Rides High After OPT-80 C. Difficile Trial Success
Optimer Pharmaceuticals saw its share price double from around $4 to $8 after it released data from a Phase III trial showing its orally dosed first-in-class macrocyclic antibiotic was at least as good as Vancocin (ViroPharma's oral vancomycin) - and possibly better - at treating the hospital scourge Clostridium difficile.
Optimer Rides High After OPT-80 C. Diff Trial Success
Phase III data show antibiotic non-inferior to Vancocin; additional trial results due mid-2009 with an NDA filing by year’s end.